Canada Markets closed

Paratek Pharmaceuticals, Inc. (PRTK)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.9300+0.0300 (+1.58%)
At close: 04:00PM EDT
1.8900 -0.04 (-2.07%)
After hours: 04:39PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close1.9000
Bid1.8900 x 1800
Ask1.9400 x 800
Day's Range1.8400 - 1.9500
52 Week Range1.7900 - 11.2400
Avg. Volume549,977
Market Cap96.865M
Beta (5Y Monthly)1.50
PE Ratio (TTM)N/A
EPS (TTM)-1.0970
Earnings DateFeb 22, 2022 - Feb 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateOct 31, 2014
1y Target Est18.50
  • GlobeNewswire

    Paratek Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

    BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced that Evan Loh, M.D., chief executive officer, will participate in a virtual fireside chat during the H.C. Wainwright Global Investment Conference. The conference will b

  • Motley Fool

    Paratek Pharmaceuticals (PRTK) Q1 2022 Earnings Call Transcript

    Participants on today's call are Evan Loh, M.D, chief executive officer; Adam Woodrow, president and chief commercial officer; and Randy Brenner, chief development and regulatory officer. Michael Bigham, executive chairman, and I will also be available for questions.

  • GlobeNewswire

    Paratek Pharmaceuticals Announces First Quarter 2022 Revenue of $24.9 Million

    -- NUZYRA® (omadacycline) Generated Net U.S. Sales of $19.9 Million from the Core Commercial Business, a 51% Increase over First Quarter 2021 -- Omadacycline Demonstrated Potent In Vitro Efficacy Against Mycobacterium Avium Complex (MAC) in a Hollow Fiber Model BOSTON, May 04, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today reported financial results and provided an update on corporate activities for the quarter ended March 31, 2022. “Our commercial execution continue